Anti-human immunodeficiency virus type 1 activity of novel 6-substituted 1-benzyl-3-(3,5-dimethylbenzyl)uracil derivatives

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 5, 2012, Pages 2581-2589

  Ordonez, Paula ^a   Hamasaki, Takayuki ^a   Isono, Yohei ^b   Sakakibara, Norikazu ^b   Ikejiri, Masahiro ^c   Maruyama, Tokumi ^b   Baba, Masanori ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b TOKUSHIMA BUNRI UNIVERSITY   (Japan)

^c OSAKA OHTANI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

6 AMINO 1 BENZYL 3 (3,5 DIMETHYLBENZYL)URACIL; 6 AZIDO 1 BENZYL 3 (3,5 DIMETHYLBENZYL)URACIL; ANTIVIRUS AGENT; UNCLASSIFIED DRUG; URACIL DERIVATIVE;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CONCENTRATION RESPONSE; CRYSTAL STRUCTURE; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2; IN VITRO STUDY; MOLECULAR DOCKING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS ISOLATION;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; BINDING SITES; CELL LINE; COMPUTER SIMULATION; DRUG RESISTANCE, VIRAL; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN STRUCTURE, TERTIARY; REVERSE TRANSCRIPTASE INHIBITORS; SEQUENCE ANALYSIS; SMALL MOLECULE LIBRARIES; T-LYMPHOCYTES; URACIL;

EID: 84860191466     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06307-11     Document Type: Article

References (61)

1. Agarwal AK, Fishwick CW. 2010. Structure-based design of antiinfectives. Ann. N. Y. Acad. Sci. 1213:20-45.
2. Archer RH, et al. 2000. Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture. J. Virol. 74:8390-8401. (Pubitemid 30666690)
3. Azijn H, et al. 2010. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTIresistant HIV-1. Antimicrob. Agents Chemother. 54:718-727.
4. Baba M, et al. 1991. Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase. Proc. Natl. Acad. Sci. U. S. A. 88:2356-2360. (Pubitemid 21916415)
5. Baba M, et al. 1994. Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro. Antimicrob. Agents Chemother. 38:688-692. (Pubitemid 24114002)
6. Balzarini J, Karlsson A, De Clercq E. 1993. Human immunodeficiency virus type 1 drug-resistance patterns with different 1-[(2-hydroxyethoxy)methyl]-6- (phenylthio)thymine derivatives. Mol. Pharmacol. 44:694-701. (Pubitemid 23317280)
7. Boyer PL, Currens MJ, McMahon JB, Boyd MR, Hughes SH. 1993. Analysis of nonnucleoside drug-resistant variants of HIV-1 reverse transcriptase. J. Virol. 67:2412-2420. (Pubitemid 23088424)
8. Buckheit RW, Jr, et al. 1995. Resistance to 1-[(2-hydroxyethoxy) methyl]-6-(phenylthio)thymine derivatives is generated by mutations at multiple sites in the HIV-1 reverse transcriptase. Virology 210:186-193.
9. Buckheit RW, Jr, et al. 2001. SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2. Antimicrob. Agents Chemother. 45:393-400. (Pubitemid 32106715)
10. Coffin JM. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267:483-489.
11. Coffin JM, Hughes SH, Varmus HE. 1997. Retroviruses. Cold Spring Harbor Laboratory Press, New York, NY.
12. Corbau R, et al. 2010. Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 54:4451-4463.
13. Das K, Jr, et al. 2004. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem. 47:2550-2560.
14. De Clercq E. 1993. HIV-1-specific RT inhibitors: highly selective inhibi- tors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase. Med. Res. Rev. 13:229-258. (Pubitemid 23114516)
15. Delaugerre C, et al. 2001. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitorcontaining regimen. J. Med. Virol. 65:445-448. (Pubitemid 32959067)
16. Delviks-Frankenberry KA, Nikolenko GN, Pathak VK. 2010. The "connection"between HIV drug resistance and RNase H. Viruses 2:1476-1503.
17. Demeter LM, et al. 2000. Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260). Antimicrob. Agents Chemother. 44:794-797. (Pubitemid 30117986)
18. Fontaine E, Vaerenbergh KV, Vandamme AM, Schmit JC. 1999. Multidrug resistant human immunodeficiency virus type 1. AIDS Rev. 1:231-237.
19. Goto J, Kataoka R, Muta H, Hirayama N. 2008. ASEDock-docking based on alpha spheres and excluded volumes. J. Chem. Infect. Model. 48:583-590. (Pubitemid 351535426)
20. Hachiya A, et al. 2008. Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors. J. Virol. 82:3261-3270. (Pubitemid 351429905)
21. Hachiya A, et al. 2009. Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naive patients. Antivir. Res. 82:115-121.
22. Halgren TA. 1999. MMFF VI. MMFF94s option for energy minimization studies. J. Comput. Chem. 20:720-729. (Pubitemid 129652635)
23. Halgren TA. 1999. MMFF VII. Characterization of MMFF94, MMFF94s, and other widely available force fields for conformational energies and for intermolecular-interaction energies and geometries. J. Comput. Chem. 20:730-748. (Pubitemid 129652636)
24. Hang JQ, et al. 2007. Substrate-dependent inhibition or stimulation of HIV RNase H activity by non-nucleoside reverse transcriptase inhibitors (NNRTIs). Biochem. Biophys. Res. Commun. 352:341-350. (Pubitemid 44838494)
25. Haraguchi K, et al. 2003. Synthesis of a highly active new anti-HIV agent 2′,3′-didehydro-3′-deoxy-4′-ethynylthymidine. Bioorg. Med. Chem. Lett. 13:3775-3777. (Pubitemid 37206505)
26. Hopkins AL, et al. 1996. Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. J. Med. Chem. 39:1589-1600.
27. Ibe S, Sugiura W. 2011. Clinical significance of HIV reverse- transcriptase inhibitor-resistance mutations. Future Microbiol. 6:295-315.
28. Isono Y, et al. 2011. Synthesis of 1-benzyl-3-(3,5-dimethylbenzyl)uracil derivatives with potential anti-HIV activity. Antivir. Chem. Chemother. 22:57-65.
29. Johnson VA, et al. 2006. Update of the drug resistance mutations in HIV-1: Fall 2006. Top. HIV Med. 14:125-130.
30. Klibanov OM, Kaczor RL. 2010. IDX-899, an aryl phosphinate-indole non-nucleoside reverse transcriptase inhibitor for the potential treatment of HIV infection. Curr. Opin. Invest. Drugs 11:237-245.
31. Lengruber RB, et al. 2011. Phenotypic characterization of drug resistance- associated mutations in HIV-1 RT connection and RNase H domains and their correlation with thymidine analogue mutations. J. Antimicrob. Chemother. 66:702-708.
32. Lightfoote MM, et al. 1986. Structural characterization of reverse transcriptase and endonuclease polypeptides of the acquired immunodeficiency syndrome retrovirus. J. Virol. 60:771-775. (Pubitemid 17174924)
33. Maruyama T, et al. 2006. Synthesis and anti-HIV-1 and anti-HCMV activity of 1-substituted 3-(3,5-dimethylbenzyl)uracil derivatives. Chem. Pharm. Bull. 54:325-333.
34. Maruyama T, et al. 2003. Synthesis and antiviral activity of 1,3-disubstituted uracils against HIV-1 and HCMV. Antivir. Chem. Chemother. 14:271-279. (Pubitemid 37509383)
35. Moyle G, et al. 2010. Phase 2a randomized controlled trial of short-term activity, safety, and pharmacokinetics of a novel nonnucleoside reverse transcriptase inhibitor, RDEA806, in HIV-1-positive, antiretroviral-naive subjects. Antimicrob. Agents Chemother. 54:3170-3178.
36. Nikolenko GN, Delviks-Frankenberry KA, Pathak VK. 2010. A novel molecular mechanism of dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors. J. Virol. 84:5238-5249.
37. Nikolenko GN, et al. 2005. Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision. Proc. Natl. Acad. Sci. U. S. A. 102:2093-2098. (Pubitemid 40262017)
38. Ntemgwa M, et al. 2007. Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine. Antimicrob. Agents Chemother. 51:3861-3869. (Pubitemid 350057782)
39. Pauwels R, et al. 1988. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 20:309-312.
40. Ren J, et al. 1995. High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nat. Struct. Biol. 2:293-302.
41. Ren J, et al. 2000. Structural basis for the resilience of efavirenz (DMP- 266) to drug resistance mutations in HIV-1 reverse transcriptase. Structure 8:1089-1094. (Pubitemid 32667472)
42. Ren J, et al. 2001. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors. J. Mol. Biol. 312:795-805. (Pubitemid 33116741)
43. Richman DD, et al. 1994. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 68:1660-1666. (Pubitemid 24065732)
44. Roquebert B, et al. 2007. Relationship between mutations in HIV-1 RNase H domain and nucleoside reverse transcriptase inhibitors resistance mutations in naive and pretreated HIV-infected patients. J. Med. Virol. 79:207-211. (Pubitemid 46213183)
45. Santos AF, et al. 2008. Conservation patterns of HIV-1 RT connection and RNase H domains: identification of new mutations in NRTI-treated patients. PLoS One 3:e1781.
46. Sarafianos SG, et al. 2009. Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. J. Mol. Biol. 385:693-713.
47. Smith JS, Roth MJ. 1992. Specificity of human immunodeficiency virus-1 reverse transcriptase-associated ribonuclease H in removal of the minusstrand primer, tRNA(Lys3). J. Biol. Chem. 267:15071-15079.
48. Spence R, Kati W, Anderson K, Johnson K. 1995. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Science 267:988-993.
49. Stanford University. HIV drug resistance database: NNRTI resistance notes. Stanford University, Stanford, CA. http://hivdb.stanford.edu/cgi-bin/ NNRTIResiNote.cgi.
50. Szczech GM, et al. 2000. Safety assessment, in vitro and in vivo, and pharmacokinetics of emivirine, a potent and selective nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44:123-130. (Pubitemid 30010681)
51. Tachedjian Orlova GM, Sarafianos SG, Arnold E, Goff SP. 2001. Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase. Proc. Natl. Acad. Sci. U. S. A. 98:7188-7193. (Pubitemid 32567924)
52. Tanaka H, et al. 1995. Synthesis and antiviral activity of 6-benzil analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 drugs. J. Med. Chem. 38:2860-2865.
53. Vingerhoets J, et al. 2010. Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS 24:503-514.
54. Waters JM, et al. 2009. Mutations in the thumb-connection and RNase H domain of HIV type-1 reverse transcriptase of antiretroviral treatmentexperienced patients. Antivir. Ther. 14:231-239.
55. Weiner SJ, et al. 1984. A new force field for molecular mechanical simulation of nucleic acids and proteins. J. Am. Chem. Soc. 106:765-784.
56. Wilkin A, et al. 17 October 2011. Long-term efficacy, safety and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviralnaive patients: week 192 results from a phase IIb randomized trial. AIDS Res. Hum. Retrovir. [Epub ahead of print].
57. Witvrouw M, et al. 1999. Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV. AIDS 13:1477-1483. (Pubitemid 29396678)
58. Wohrl BM, Moelling K. 1990. Interaction of HIV-1 ribonuclease H with polypurine tract containing RNA-DNA hybrids. Biochemistry 29:10141-10147. (Pubitemid 20384518)
59. Yap SH, et al. 2007. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med. 4:e335.
60. Zhan P, et al. 2011. HIV-1 NNRTIs: structural diversity, pharmacophore similarity, and implications for drug design.Med.Res. Rev. doi:10.1002/med.
61. Zhou XJ, et al. 2009. Single-dose escalation and multiple-dose safety, tolerability, and pharmacokinetics of IDX899, a candidate human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor, in healthy subjects. Antimicrob. Agents Chemother. 53:1739-1746.